The inDrop technology enables researchers to run full transcriptomic analysis with single cells. Rather than binding the full spectrum of mRNAs, this new programme provides custom targeted beads to capture transcripts of a very specific set of user-selected genes within single cells.
Some of the potential applications for the targeted beads might be custom oncogene panels, immunoprofiling for antibodies and T-cell receptors, or mRNA isoform detection.
1CellBio is a single-cell analysis company serving the biomedical research community.
The company's flagship inDrop System, a high-resolution, single-cell transcriptomics platform, delivers greater experimental control, rare actionable information and lower overall cost per result compared to all other existing platforms.
Research laboratories around the world are now adopting the platform for a range of single-cell applications from tumor profiling to stem cells to embryo development to the identification and validation of new drug targets.
Founded by a group of prominent scientists at Harvard University, 1CellBio is based in Watertown, Mass., and the company supports its growing number of customers through a team of international sales and field application scientists.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval